London, UK – GHO Capital, the European specialist healthcare investor, today announces the acquisition of Quotient Clinical (Quotient or the Company), a provider of outsourced, early-stage drug development services to the pharmaceutical industry.
Headquartered in the UK and employing over 280 professionals, Quotient Clinical enables pharmaceutical and biotechnology customers to improve research and development productivity and accelerate drug development timelines.
Quotient Clinical’s Translational Pharmaceutics® platform offers a differentiated service proposition in the form of an integrated approach to drug formulation development, “real-time” manufacturing and clinical testing within a single location. With significant time and cost savings, customers are able to bring drug products to market faster. The specific benefits of Translational Pharmaceutics® include: i) reducing development timelines for customers; ii) reducing costs by conserving drug substance through precise dose selection and formulation modification in response to emerging clinical data; and iii) simplifying the supply chain for customers.
Quotient has a strong customer base, providing support to a range of top-tier pharmaceutical companies and small-medium sized biotechnology companies. The Company has 52,000 ft2 of integrated operating facilities in Nottingham for pharmaceutical sciences and clinical trials, and a data sciences function based in Edinburgh which includes medical writing, statistics and programming. Quotient’s state-of-the-art facilities are approved to Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards with scalable technologies and processes.
The outsourced early-stage drug development market is expected to grow strongly over the next five years, primarily driven by growth in the number of compounds entering development, a favourable funding environment for biotechnology companies and new challenges in drug development. With attractive market dynamics and a global customer base, Quotient is uniquely-positioned to deliver international growth.
Mike Mortimer, Executive Partner and Founder at GHO Capital, said: “The outsourced services and contract development and manufacturing organisation space is one that GHO Capital knows extremely well. Quotient Clinical has a highly attractive business model which can be scaled and expanded across Europe and in the USA in particular, making this an excellent investment opportunity for our fund. We look forward to working with the management team to further support the Company’s internationalisation.”